Related Experiment Videos
Successful treatment of severe carbamyl phosphate synthetase I deficiency
Archives of Disease in Childhood
|December 1, 1984
Insights
Neonatal hyperammonaemia caused by carbamyl phosphate synthetase I deficiency was treated with protein restriction and medication. The patient shows normal growth and development at 15 months, indicating successful management of urea cycle disorder.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Neonatal hyperammonaemia is a serious condition often caused by urea cycle defects.
- Carbamyl phosphate synthetase I (CPS1) deficiency is a rare genetic disorder affecting ammonia metabolism.
Observation:
- A case study of a female infant diagnosed with neonatal hyperammonaemia.
- The patient presented with symptoms indicative of carbamyl phosphate synthetase I deficiency.
Findings:
- Treatment involved early protein restriction from the second day of life.
- Therapeutic interventions included sodium benzoate and sodium phenylacetate to enhance protein tolerance.
- The patient achieved normal growth and developmental milestones by 15 months of age.
Implications:
- This case highlights the efficacy of a combined therapeutic approach for CPS1 deficiency.
- Early diagnosis and management are crucial for favorable long-term outcomes in urea cycle disorders.
- The successful management suggests potential for improved quality of life for affected individuals.
Abstract:
We describe a girl with neonatal hyperammonaemia due to carbamyl phosphate synthetase I deficiency. Treatment consisted of protein restriction from the second day of life. Sodium benzoate was given for three weeks after birth and again from 7 months of age together with sodium phenylacetate to improve protein tolerance. Growth and development are normal at 15 months of age.